See What HealthDay Can Do For You
Contact Us

Bemiparin Deemed Effective After Gynecological Operations

The drug appears to prevent venous thromboembolism after benign gynecological surgery

blood cells

TUESDAY, Nov. 3, 2015 (HealthDay News) -- Bemiparin is effective for preventing venous thromboembolism (VTE) after benign gynecological surgery, according to a study published online Oct. 31 in the Journal of Thrombosis and Haemostasis.

Shahla K. Alalaf, M.D., from Hawler Medical University in Erbil City, Iraq, and colleagues randomized women at moderate, high, and highest risk for developing VTE after benign gynecological surgery to receive either seven daily doses of 3,500 IU of subcutaneous bemiparin (387 patients) or standard rehydration and advice on ambulation (387 patients). Patients were assessed at seven and 30 days postoperatively for symptomatic VTE, confirmed with imaging.

The researchers found that the incidence of symptomatic VTE (deep vein thrombosis and pulmonary embolism) events was lower among participants who received bemiparin (0/377) than those who received no pharmacological intervention (12/380). Logistic regression analysis showed there were significant associations between VTE and immobility (odds ratio, 7.1), varicose veins (odds ratio, 16.8), and thrombophilia (odds ratio, 39.3). Bemiparin use was not tied to major bleeding events or side effects.

"Bemiparin was an effective thromboprophylactic agent for preventing venous thrombosis after benign gynecological surgery," the authors write.

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.